Hot Promising Stocks To Watch Right Now

On Tuesday, Amgen (NASDAQ: AMGN  ) will release its latest quarterly results. The key to making smart investment decisions on stocks reporting earnings is to anticipate how they'll do before they announce results, leaving you fully prepared to respond quickly to whatever inevitable surprises arise. That way, you'll be less likely to make an uninformed knee-jerk reaction to news that turns out to be exactly the wrong move.

Amgen has a strong reputation as a giant in the biotech field, having been a pioneer in the industry. Yet the company hasn't stopped striving for further growth as it pushes its efforts into promising new corners of the biologics market. Let's take an early look at what's been happening with Amgen over the past quarter and what we're likely to see in its quarterly report.

Hot Growth Companies To Buy For 2015: Ambit Biosciences Corp (AMBI)

Ambit Biosciences Corporation, incorporated on May 17, 2000, is a biopharmaceutical company. The Company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, autoimmune and inflammatory diseases by inhibiting kinases that are important drivers for those diseases. The Company�� lead drug candidate, quizartinib, is in Phase IIb clinical development in patients with relapsed/refractory acute myeloid leukemia (AML). The Company�� second drug candidate in clinical development, AC410, is a potent, selective, orally-administered, small molecule inhibitor of Janus kinase 2 (JAK2) that has potential utility for the treatment of autoimmune and inflammatory diseases. The Company�� third program consists of two selective small molecule compounds, AC708 and AC855, which inhibit the colony-stimulating factor-1 receptor (CSF1R), a receptor tyrosine kinase.

Quizartinib

The Company�� lead drug candidate, quizartinib, is a once-daily, orally-administered, potent and selective inhibitor of FLT3, a validated target in the treatment of AML, and is in Phase IIb clinical development. The FLT3-ITD mutation acts like a power switch that causes leukemic cells, or blasts, to spread more aggressively and grow back more rapidly following chemotherapy, conferring an especially poor survival outcome. Quizartinib is designed to turn off this switch. The Company is developing a companion diagnostic test with Genoptix Medical Laboratory, a Novartis company, to identify FLT3-ITD positive patients.

AC410

The Company�� advanced drug candidate, AC410, is a potent, selective, orally-administered, small molecule inhibitor of JAK2, which has potential utility for the treatment of autoimmune and inflammatory diseases. Signaling through JAK controls the activation, proliferation and survival of various types of immune cells, and overactivation of such cells can exacerbate a range of normal inflammatory processes, resulting i! n inflammation. The Company�� initial JAK2 drug candidate, AC430, is a racemic mixture (50/50) of two enantiomers (mirror images), AC410 and AC409, and was studied in a Phase I clinical trial.

CSF1R Program

The Company is developing two potent and exquisitely selective small molecule compounds, AC708 and AC855 that both inhibit CSF1R and have potential utility in oncology, autoimmune and inflammatory diseases. Signaling through CSF1R controls the activation, proliferation and survival of macrophages, which are key mediators of immune system function and over-activation of macrophages, may result in exacerbation of certain diseases.

The Company competes with Abbvie Inc., Akinion Pharmaceuticals AB, Amgen Inc., ARIAD Pharmaceuticals, Inc., AROG Pharmaceuticals, LLC, ArQule, Inc., Astellas, AstraZeneca plc, Bayer AG, Celgene Corporation, Daiichi-Sankyo Company Limited, Galapagos NV, GlaxoSmithKline plc, Incyte Corporation, Janssen Pharmaceuticals, Inc., Johnson & Johnson, Eli Lilly and Company, Novartis, Onyx Pharmaceuticals, Inc., Pfizer, Rigel Pharmaceuticals, Inc., F. Hoffman-LaRoche Ltd, and Vertex Pharmaceuticals Incorporated.

Advisors' Opinion:

• [By Wallace Witkowski]

  Ambit Biosciences Corp. (AMBI) �shares fell more than 37% to $8 in moderate volume. The small-cap biotech said it will not file an accelerated approval application with the Food and Drug Administration for its leukemia drug quizartinib after the agency disagreed with the company about the use of certain study data to support the drug�� efficacy.

Hot Promising Stocks To Watch Right Now: Seabridge Gold Inc (SA)

Seabridge Gold Inc. (Seabridge) is a development-stage company. The Company is engaged in the acquisition and exploration of gold properties located in North America. As of December 31, 2011, the Company held six properties with gold resources and its material properties are its KSM Project and its Courageous Lake Project. The Company holds a 100% interest in each of its properties. Its projects include KSM (Kerr-Sulphurets-Mitchell), Courageous Lake, Pacific Intermountain Gold, Grassy Mountain, Red Mountain, Quartz Mountain, Castle Black Rock and Other Nevada projects. The KSM project consists of two contiguous claim blocks in the Iskut-Stikine region in British Columbia, approximately 20 kilometers southeast of the Eskay Creek Mine. The Courageous Lake project is a gold project covering approximately 81,700 acres located in the Northwest Territories, Canada. Advisors' Opinion:

• [By Lisa Levin]

  Gold: This industry rose 1.44% by 10:40 am ET. The top performer in this industry was Seabridge Gold (NYSE: SA), which gained 11.3%. Seabridge Gold shares have dropped 60.24% over the past 52 weeks, while the S&P 500 index has gained 26.39% in the same period.

Hot Promising Stocks To Watch Right Now: Pzena Investment Management Inc (PZN)

Pzena Investment Management, Inc. is a publicly owned investment manager. The firm also provides investment advisory services to funds. It provides its services to individuals, typically high net worth individuals; investment companies; charitable organizations; corporations; state or municipal government entities; pension and profit sharing plans; and pooled investment vehicles. The firm manages separate client-focused equity portfolios. It invests in the public equity markets across the globe. The firm primarily invests in value stocks of large-cap, mid-cap, and small-cap companies. It employs fundamental analysis while making its investments. Pzena Investment Management, Inc. was founded in 1995 and is based in New York, New York.

Advisors' Opinion:

• [By Serena Saitto]

  Officials at another Dell shareholder, Pzena Investment Management Inc. (PZN), which has opposed the buyout, didn�� return calls seeking comment.

• [By Bristol Voss]

  Pzena Investment Management (NYSE: PZN) is an investment manager catering to wealthy families and other institutions. It has the largest market cap at $85.4 million, and its share price, although the highest at about $7, buys the most market cap per dollar of the three. It has a forward P/E of 14 and a dividend yield of 1.7%. For the most recent quarter, revenue grew 5.4% and earnings were flat. Although Pzena's gross profit margin was down from the previous year, it remains a very high 45.2%.

Hot Promising Stocks To Watch Right Now: Julius Baer Gruppe AG (BAER)

Julius Baer Gruppe AG (the Group) is a Switzerland-based private banking group, with an exclusive focus on servicing and advising private clients and independent asset managers. The Group has a global presence with approximately 50 locations in more than 25 countries and jurisdictions. Julius Baer Gruppe AG was established through spin off from Julius Baer Holding AG�� businesses into two independent entities, namely the Company, together with its subsidiaries, comprising Bank Julius Baer & Co Ltd as its principal operating entity, and GAM Holding, together with its subsidiaries, comprising GAM and the Julius Baer-branded asset management business, which includes the private label funds business that formerly was part of Julius Baer Holding Ltd�� Bank Julius Baer segment. The Group diversifies its operations into geographical segments, including Switzerland, rest of Europe, Americas, and Asia and Other Countries. Advisors' Opinion:

• [By Corinne Gretler]

  Julius Baer Group Ltd. (BAER) rallied 5.7 percent to 42.04 francs. Switzerland�� third-biggest wealth manager said increased client trading boosted margins as it integrated Merrill Lynch businesses acquired from Bank of America Corp. last year. The gross margin, which reflects how much the bank makes in revenue on managed client assets, rose to 102 basis points in the first half, from 98 basis points in the year-earlier period.